Patent · US Active

Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells

US8263065B2 · kind B2 · utility

23Cited by

165References

36Claims

0Family size

Assignee

Anthrogenesis Corporation · US

Inventors

Robert J. Hariri · New York, US
Mohammad Heidaran · Chatham, US
Lin Kang · Beijing, CN
Neerav D. PADLIYA · Scotch Plains, US
Ajai Pal · Bound Brook, US
Vanessa Voskinarian-Berse · Millington, US
Andrew Zeitlin · Green Brook, US
Xiaokui Zhang · Northborough, US

Key dates

Filing date	Sep 29, 2008
Grant date	Sep 11, 2012
Priority date	—
Expiry date	Nov 14, 2029

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K2239/52
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided herein are placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, and placenta-derived intermediate natural killer cells, and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.